ACRIN Study Endorses Virtual Colonoscopy - Validation for Colon CAD Software Maker Medi...( NEW YORK Oct. 3 /- MGT Capital In...),Health

NEW YORK, Oct. 3 /PRNewswire-FirstCall/ -- MGT Capital Investments, Inc. (Amex: MGT), an investment company focused on the Healthcare Information Technology ("HCIT") sector, announced today that the ACRIN study endorses virtual colonoscopy for Medicsight PLC (subsidiary of MGT). Medicsight PLC (AIM: MDST), an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, draws attention to the recent announcement of preliminary results of the National U.S. Computerised Tomography (CT) Colonography Trial (ACRIN study 6664). The results are expected to lead to wider adoption of CT colonography (also known as virtual colonoscopy) as routine screening for colorectal cancer.

David Sumner, Chief Executive of Medicsight, said, "We welcome the results of this landmark study, confirming that CT colonography is a genuine and robust option in the armamentarium that physicians have at their disposal when screening for colorectal cancer. This is likely to lead to a material increase in the use of CT colonography for screening populations aged 50 or more who are most at risk of developing this devastating condition. Medicsight's ColonCAD(TM) software, which can be used with multi-detector CT imaging equipment, helps radiologists to interpret the CT scans and identify early- stage lesions. We expect the Company and its CAD software to be an important beneficiary of this trend."

The U.S. trial has compared the detection of polyps and early-stage cancer of the colon using either conventional optical colonoscopy or CT colonography, in which X-ray slice images are reconstructed by computer to provide a virtual image of the colon.
'/>"/>